Evaluation of Endocrine Therapy-Induced Alopecia Among Postmenopausal and Premenopausal Female Patients With Breast Cancer

Evaluation of Endocrine Therapy-Induced Alopecia Among Postmenopausal and Premenopausal Female Patients With Breast Cancer

PRIMARY OBJECTIVE:
I. To describe the incidence, characteristics, and severity of alopecia related to endocrine therapy in four cohorts of postmenopausal women who have had a diagnosis of breast cancer: patients undergoing endocrine therapy with tamoxifen, patients undergoing endocrine therapy with an aromatase inhibitor, patients undergoing therapy with an aromatase inhibitor in addition to a CDK4/6 inhibitor, and patients not receiving endocrine therapy. A fifth cohort of patients will also be included, consisting of premenopausal women receiving any type of endocrine therapy.
SECONDARY OBJECTIVE:
I. To investigate the difference in incidence, characteristics, and severity of alopecia between the aforementioned five cohorts of patients.
OUTLINE: This is an observational study.
Patients complete alopecia questionnaires and surveys on study.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 15, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments